Sugi Predict

Sugi Predict / Compounds / SCHEMBL7600347

SCHEMBL7600347

SCHEMBL7600347

Brc1ccc2cc(-c3cnc(C4CCCC4)[nH]3)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.43
▸ MAPK13 O15264 1/20 0.41
▸ MAPK12 P53778 1/20 0.41
▸ MAPK11 Q15759 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ HPGDS O60760 5/20 0.40
▸ PYGL P06737 2/20 0.40
▸ RPS6KB1 P23443 4/20 0.39
▸ AKT1 P31749 3/20 0.39
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ TTK P33981 2/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ TLR9 Q9NR96 1/20 0.36
▸ TLR8 Q9NR97 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7605047 0.87 SCN10A (0.38) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL7604946 0.86 HPGDS (0.43) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL9977195 0.86 MAPK13 (0.52) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL19697871 0.85 MAPK13 (0.40) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL17014412 0.84 MAPK13 (0.51) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL10144846 0.84 MAPK13 (0.51) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL7602073 0.83 HPGDS (0.48) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL204798 0.82 MAPK13 (0.46) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL2706498 0.82 MAPK13 (0.46) SCN10AMAPK13MAPK12MAPK11MAPK14
SCHEMBL15430158 0.82 MAPK13 (0.41) SCN10AMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353529-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2015-12-10 — — US disclosed
US-9156823-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2015-10-13 — — US disclosed
US-20150203474-A1 SOLID FORMS COMPRISING INHIBITORS OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH PRESIDIO PHARMACEUTICALS, INC. 2015-07-23 — — US disclosed
US-20150057218-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS INC (US) 2015-02-26 — — US disclosed
US-20150038501-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. 2015-02-05 — — US disclosed
US-8921369-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-12-30 — — US disclosed
US-8877707-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-8865756-B2 Inhibitors of HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2014-10-21 — — US disclosed
US-20140018313-A1 ANTIVIRAL COMPOUNDS Gelead Sciences, Inc. 2014-01-16 — — US disclosed
US-20130310427-A1 INHIBITORS OF HCV NS5A PROTEIN PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-21 — — US disclosed
US-20130296311-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-11-07 — — US disclosed
US-20130203656-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-08-08 — — US disclosed
US-20130096101-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2013-04-18 — — US disclosed
US-20120122864-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20120115855-A1 INHIBITORS OF HCV NS5A PRESIDIO PHARMACEUTICALS, INC. (US) 2012-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018313-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 SCN10A 4642/4885MAPK13 3853/4885MAPK12 3385/4885
US-20130310427-A1 INHIBITORS OF HCV NS5A PROTEIN HAVCR2, EIF2AK2, PPP2CA SCN10A 2912/4885MAPK13 1423/4885MAPK12 2076/4885
US-20130296311-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885
US-20130096101-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3491/4885MAPK13 2158/4885MAPK12 2107/4885
US-20120122864-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885
US-20150057218-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885
US-20150353529-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 SCN10A 4642/4885MAPK13 3853/4885MAPK12 3385/4885
US-20150038501-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885
US-20150203474-A1 SOLID FORMS COMPRISING INHIBITORS OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH ABL1, HAVCR2, MAVS SCN10A 3726/4885MAPK13 2713/4885MAPK12 3015/4885
US-20130203656-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885
US-20120115855-A1 INHIBITORS OF HCV NS5A HAVCR2, MAVS, EIF2AK2 SCN10A 3547/4885MAPK13 2347/4885MAPK12 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.